Blocking of human immunodeficiency virus infection depends on cell density and viral stock age
- PMID: 1674549
- PMCID: PMC240987
- DOI: 10.1128/JVI.65.6.3293-3300.1991
Blocking of human immunodeficiency virus infection depends on cell density and viral stock age
Abstract
Quantitative infectivity assays were used to study how the blocking activity of soluble CD4 (sCD4) is affected by sCD4 concentration, target cell density, and viral stock age. During incubation with 20 nM sCD4, human immunodeficiency virus type 1 (HIV-1) stocks underwent irreversible inactivation. In contrast, inactivation with 2 nM sCD4 was almost entirely reversible. At lower sCD4 concentrations (less than or equal to 2 nM) and target cell densities of 6.25 x 10(4) ml-1, sCD4 blocking activity for HIV-1 gave a gp120-sCD4 association constant (Kassoc) of 1.7 x 10(9) M-1, which agrees with chemical measurements. At the higher density of 1.6 x 10(7) cells ml-1, however, the blocking activity was 20-fold less. During incubation of HIV-1 stock optimized for infectivity by rapid harvest, sCD4 blocking activity increased 20-fold during a 3-h window. These results show that competitive blocking activity depends strongly on target cell density and virion age. Thus, unappreciated variations in HIV stocks and assay conditions may hinder comparisons of blockers from laboratory to laboratory, and the age of HIV challenge stocks may influence studies of drug and vaccine efficacy. The results also suggest that blocking of viral particles in lymphoid compartments will require very high competitive blocker concentrations, which may explain the refractory outcomes from sCD4-based drug trials in humans.
Similar articles
-
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.J Virol. 1991 Mar;65(3):1133-40. doi: 10.1128/JVI.65.3.1133-1140.1991. J Virol. 1991. PMID: 1995942 Free PMC article.
-
Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity.AIDS Res Hum Retroviruses. 1991 Dec;7(12):975-81. doi: 10.1089/aid.1991.7.975. AIDS Res Hum Retroviruses. 1991. PMID: 1687500
-
Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.J Virol. 1993 Mar;67(3):1461-71. doi: 10.1128/JVI.67.3.1461-1471.1993. J Virol. 1993. PMID: 8437224 Free PMC article.
-
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.J Virol. 1992 Jan;66(1):235-43. doi: 10.1128/JVI.66.1.235-243.1992. J Virol. 1992. PMID: 1727487 Free PMC article.
-
CD4-gp120 interactions.Curr Opin Immunol. 1991 Aug;3(4):552-8. doi: 10.1016/0952-7915(91)90020-2. Curr Opin Immunol. 1991. PMID: 1721822 Review.
Cited by
-
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.J Virol. 1997 Feb;71(2):883-90. doi: 10.1128/JVI.71.2.883-890.1997. J Virol. 1997. PMID: 8995604 Free PMC article.
-
Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7581-5. doi: 10.1073/pnas.89.16.7581. Proc Natl Acad Sci U S A. 1992. PMID: 1323844 Free PMC article.
-
Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.Virology. 2007 Dec 20;369(2):245-62. doi: 10.1016/j.virol.2007.06.044. Epub 2007 Sep 7. Virology. 2007. PMID: 17825343 Free PMC article.
-
Molecular determinants of the ratio of inert to infectious virus particles.Prog Mol Biol Transl Sci. 2015;129:285-326. doi: 10.1016/bs.pmbts.2014.10.012. Epub 2014 Dec 1. Prog Mol Biol Transl Sci. 2015. PMID: 25595808 Free PMC article. Review.
-
Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).Drugs. 1993 May;45(5):637-53. doi: 10.2165/00003495-199345050-00002. Drugs. 1993. PMID: 7686460 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials